Thursday, March 26, 2009 11:20:50 AM
*ALTU .23 (iftrko) pp=.22 s=.21 r=.25
Altus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders. The company develops its protein therapeutics using its proprietary protein crystallization and cross-linking technology, which enables the delivery of protein therapeutics through the oral and parenteral routes of delivery. Its lead products under development include Trizytek (liprotamase), which is in Phase III efficacy clinical trials in cystic fibrosis patients for the treatment of malabsorption due to exocrine pancreatic insufficiency, as well as in two long-term Phase III safety studies; ALTU-238 that completed Phase II clinical trials in adults for the treatment of growth hormone deficiency; and ALTU-237, a Phase I clinical trial completed product for the treatment of hyperoxalurias. The company also has a pipeline of other product candidates in preclinical research and development, which include ALTU-236, an orally administered, cross-linked enzyme crystal formulation of a phenylalanine degrading enzyme for the treatment and prevention of hyperphenylalaninemia due to phenylketonuria; and ALTU-242, an orally administered enzyme developed primarily to reduce long-term effects resulting from excess levels of urate, which might precipitate into urate crystals, and accumulate in joints leading to painful erosive arthritis, also known as gout. Altus Pharmaceuticals has a strategic alliance agreement with Cystic Fibrosis Foundation Therapeutics, Inc. to collaborate on the development of Trizytek and specified derivatives of Trizytek in North America. The company, formerly known as Altus Biologics, Inc., was incorporated in 1992 and is headquartered in Waltham, Massachusetts.
Altus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders. The company develops its protein therapeutics using its proprietary protein crystallization and cross-linking technology, which enables the delivery of protein therapeutics through the oral and parenteral routes of delivery. Its lead products under development include Trizytek (liprotamase), which is in Phase III efficacy clinical trials in cystic fibrosis patients for the treatment of malabsorption due to exocrine pancreatic insufficiency, as well as in two long-term Phase III safety studies; ALTU-238 that completed Phase II clinical trials in adults for the treatment of growth hormone deficiency; and ALTU-237, a Phase I clinical trial completed product for the treatment of hyperoxalurias. The company also has a pipeline of other product candidates in preclinical research and development, which include ALTU-236, an orally administered, cross-linked enzyme crystal formulation of a phenylalanine degrading enzyme for the treatment and prevention of hyperphenylalaninemia due to phenylketonuria; and ALTU-242, an orally administered enzyme developed primarily to reduce long-term effects resulting from excess levels of urate, which might precipitate into urate crystals, and accumulate in joints leading to painful erosive arthritis, also known as gout. Altus Pharmaceuticals has a strategic alliance agreement with Cystic Fibrosis Foundation Therapeutics, Inc. to collaborate on the development of Trizytek and specified derivatives of Trizytek in North America. The company, formerly known as Altus Biologics, Inc., was incorporated in 1992 and is headquartered in Waltham, Massachusetts.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
